Independent fund research. Built on SEC filings.

How we research funds

Mutual fund · Mid-Cap · Nuveen / TIAA

Nuveen Small/Mid Cap Growth Opportunities Fund Class A (FRSLX)

Ticker FRSLX · Since 1995-01-09 · · Holdings as of Jul 31, 2026

Expense ratio
1.13%$113/yr per $10k
5-yr return
+0.1%annualized
1-yr return
+1.5%as of Dec 2025
Net assets
$162.3Mall share classes
Holdings
82

Bottom line

Is FRSLX a good fund? The bottom line

FRSLX is the Class A share class of Nuveen Small/Mid Cap Growth Opportunities Fund, a managed mid-cap mutual fund from Nuveen / TIAA.

Annual fees run 1.13% — about $113 a year on every $10,000 invested, more expensive than 72% of mid-cap funds we track.

It returned +1.5% over one year, +0.1% a year over five years, +8.4% a year over ten (as of Dec 31, 2025, per its prospectus).

With $162 million in net assets and 82 holdings, its largest position is Impinj Inc (2.0%) and the top 10 make up 17.7% of the portfolio.

This share class carries a front-end sales charge of up to 5.75%; a no-load class or ETF alternative can avoid it.

What to watch

  • Expensive for its category (1.13%)
  • 5-year return in the bottom quarter of its category
  • Front-end sales load up to 5.75%
  • 12b-1 marketing fee of 0.25% a year
  • High turnover (119% a year) can mean more taxable distributions

Updated Nov 19, 2026

What FRSLX invests in

The investment objective of the Fund is capital appreciation.

Under normal circumstances, the Fund invests at least 80% of the sum of its net assets and the amount of any borrowings for investment purposes in equity securities of small-capitalization and mid-capitalization growth companies. Small-capitalization and mid-capitalization companies are defined as companies that have market capitalizations within the market capitalization range of the companies in the Russell 2500 Index. The market capitalization range is determined based on the companies in the index as of the last business day of the month in which the index was most recently reconstituted and may be updated to reflect any changes to the index composition and the market capitalization of companies in the index. Growth companies are those that are constituents of at least one of the following indexes on the last business day of the month in which its most recent reconstitution was…

From the fund's prospectus (filed Feb 27, 2026).

FRSLX performance

Fund calendar-year total returns, 2016–2025 2016: +1.2%; 2017: +24.5%; 2018: −9.1%; 2019: +33.4%; 2020: +46.0%; 2021: +4.3%; 2022: −30.3%; 2023: +19.9%; 2024: +13.4%; 2025: +7.6% +1% 2016 +24% 2017 −9% 2018 +33% 2019 +46% 2020 +4% 2021 −30% 2022 +20% 2023 +13% 2024 +8% 2025
Fund gain (+) Fund loss (−)
Average annual total returns
1 yr5 yr10 yr
FRSLX+1.5%+0.1%+8.4%
Mid-Cap median+7.9%+8.1%+9.9%

Source: Fund prospectus, as of Dec 31, 2025

Full FRSLX performance history →

What FRSLX costs

On a $10,000 investment, FRSLX's 1.13% expense ratio costs about $113 a year. The prospectus estimates $1,957 in total costs over 10 years (assuming 5% annual returns). The median mid-cap fund charges 0.88%.

See the full FRSLX fee table →

FRSLX top 10 holdings

#Holding% of fund
1Impinj Inc1.96%
2FirstCash Holdings Inc1.94%
3Encompass Health Corp1.82%
4Guardant Health Inc1.79%
5Agilysys Inc1.78%
6Merit Medical Systems Inc1.77%
7HealthEquity Inc1.75%
8ATI Inc1.63%
9Axsome Therapeutics Inc1.62%
10Applied Industrial Technologies Inc1.61%

Source: SEC Form N-PORT, period ended Jul 31, 2026

The top 10 make up 17.7% of the fund. See all top 25 holdings and asset mix →

Alternatives to FRSLX

More funds like FRSLX →

FRSLX FAQ

What is the expense ratio of FRSLX?
FRSLX's expense ratio is 1.13%, which works out to about $113 a year for every $10,000 invested. The prospectus estimates total costs of $1,957 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is FRSLX a good investment?
It depends on your goals, but the data points to: expensive for its category (1.13%); 5-year return in the bottom quarter of its category; front-end sales load up to 5.75%; 12b-1 marketing fee of 0.25% a year; high turnover (119% a year) can mean more taxable distributions. This is general information, not personalized advice.
What does FRSLX hold?
FRSLX's largest holdings are Impinj Inc (2.0%), FirstCash Holdings Inc (1.9%), Encompass Health Corp (1.8%), Guardant Health Inc (1.8%), Agilysys Inc (1.8%). It holds 82 positions in total as of Jul 31, 2026 (SEC Form N-PORT).
What is FRSLX's 5-year return?
FRSLX returned +0.1% a year over the five years ending Dec 31, 2025, and +8.4% a year over ten years. Past performance does not guarantee future results.
Does FRSLX have a sales load?
Yes. FRSLX has a maximum front-end sales charge of 5.75%.
Who manages FRSLX?
FRSLX is offered by Nuveen / TIAA through Nuveen Investment Funds Inc.